Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07551778 by BOE Technology Group Co., Ltd., with a registry enrolment figure of 42 participants, started 2026-08 and due to reach its primary completion in 2028-04. Interventions recorded: NK Cells; NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy; NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy; NK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapy; NK cells + PD-(L)1 inhibitor + capecitabine or S-1 as first-line maintenance therapy. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); Colorectal Cancer; Advanced Solid Tumors; Advanced Hepatocellular Carcinoma (HCC); GC/GEJC. Primary outcome: Dose-Limiting Toxicity (DLT); Adverse Events (AE). Colorectal eligibility wording from the registry: "* Histologically/cytologically confirmed locally advanced unresectable or metastatic (unresectable Stage III or Stage IV per AJCC 8th Edition) colorectal adenocarcinoma;". No results are recorded here; the registry entry is the source.